Clinical trial
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy
NCT05280548 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- May 3, 2022
- Completion date
- December 6, 2027
- Enrollment
- 104 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.